XOMA Corp is a biotechnology business based in the US. XOMA shares (XOMA) are listed on the NASDAQ and all prices are listed in US Dollars. XOMA employs 12 staff and has a trailing 12-month revenue of around $41 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $17.00 |
|---|---|
| 52-week range | $15.68 - $32.09 |
| 50-day moving average | $20.04 |
| 200-day moving average | $21.42 |
| Wall St. target price | $62.50 |
| PE ratio | 19.7674 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.86 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $17 from 2022-09-23
| 1 week (2022-09-20) | -3.95% |
|---|---|
| 1 month (2022-08-26) | -10.76% |
| 3 months (2022-06-27) | -22.34% |
| 6 months (2022-03-24) | -38.67% |
| 1 year (2021-09-27) | -32.94% |
|---|---|
| 2 years (2020-09-25) | -9.86% |
| 3 years (2019-09-27) | 18.76 |
| 5 years (2017-09-27) | 19.3 |
Valuing XOMA stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XOMA's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
XOMA's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, XOMA shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
XOMA's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.2 million.
The EBITDA is a measure of a XOMA's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $41 million |
|---|---|
| Operating margin TTM | 49.27% |
| Gross profit TTM | $38 million |
| Return on assets TTM | 8.7% |
| Return on equity TTM | 14.68% |
| Profit margin | 45.05% |
| Book value | $11.81 |
| Market capitalisation | $194.7 million |
TTM: trailing 12 months
We're not expecting XOMA to pay a dividend over the next 12 months.
XOMA's shares were split on a 1:20 basis on 17 October 2016. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XOMA shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for XOMA shares which in turn could have impacted XOMA's share price.
Over the last 12 months, XOMA's shares have ranged in value from as little as $15.68 up to $32.085. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XOMA's is 0.9457. This would suggest that XOMA's shares are less volatile than average (for this exchange).
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.